START OF PAGE 1
WES MOORE, Governor Ch. 323

Chapter 323

(House Bill 1217)

AN ACT concerning

Maryland Medical Assistance Program and Health Insurance – Required
Coverage for Biomarker Testing

FOR the purpose of requiring the Maryland Medical Assistance Program and certain
insurers, nonprofit health service plans, health maintenance organizations, and
managed care organizations to provide coverage for biomarker testing that is
supported by medical and scientific evidence; establishing requirements for
deductibles, copayments, coinsurance, and utilization review for biomarker testing;
and generally relating to the coverage of biomarker testing by the Maryland Medical
Assistance Program and health insurance carriers.

BY adding to
Article – Health – General
Section 15–102.3(k) and 15–103(a)(2)(xxii)
Annotated Code of Maryland
(2019 Replacement Volume and 2022 Supplement)

BY repealing and reenacting, without amendments,
Article – Health – General
Section 15–103(a)(1)
Annotated Code of Maryland
(2019 Replacement Volume and 2022 Supplement)

BY repealing and reenacting, with amendments,
Article – Health – General
Section 15–103(a)(2)(xx) and (xxi)
Annotated Code of Maryland
(2019 Replacement Volume and 2022 Supplement)

BY adding to
Article – Insurance
Section 15–859
Annotated Code of Maryland
(2017 Replacement Volume and 2022 Supplement)

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
That the Laws of Maryland read as follows:

Article – Health – General

15–102.3.
– 1 –
END OF PAGE 1

START OF PAGE 2
Ch. 323 2023 LAWS OF MARYLAND

(K) THE BEGINNING JULY 1, 2025, THE PROVISIONS OF § 15–859 OF THE
INSURANCE ARTICLE APPLY TO MANAGED CARE ORGANIZATIONS IN THE SAME
MANNER THEY APPLY TO CARRIERS.

15–103.

(a) (1) The Secretary shall administer the Maryland Medical Assistance
Program.

(2) The Program:

(xx) Beginning on July 1, 2023, shall provide, subject to federal
approval and limitations of the State budget, community violence prevention services in
accordance with § 15–141.3 of this subtitle; [and]

(xxi) Beginning on January 1, 2023, shall provide, subject to the
limitations of the State budget, and as permitted by federal law, coverage for self–measured
blood pressure monitoring for all Program recipients diagnosed with uncontrolled high
blood pressure, including:

1. The provision of validated home blood pressure monitors;
and

2. Reimbursement of health care provider and other staff
time used for patient training, transmission of blood pressure data, interpretation of blood
pressure readings and reporting, and the delivery of co–interventions, including
educational materials or classes, behavioral change management, and medication
management; AND

(XXII)BEGINNING ON JANUARY 1, 2024 JULY 1, 2025, SHALL
PROVIDE, SUBJECT TO THE LIMITATIONS OF THE STATE BUDGET, AND AS
PERMITTED BY FEDERAL LAW, COVERAGE FOR BIOMARKER TESTING IN
ACCORDANCE WITH § 15–859 OF THE INSURANCE ARTICLE.

Article – Insurance

15–859.

(A) (1) IN THIS SECTION THE FOLLOWING WORDS HAVE THE MEANINGS
INDICATED.

(2) (I) “BIOMARKER” MEANS A CHARACTERISTIC THAT IS
OBJECTIVELY MEASURED AND EVALUATED AS AN INDICATOR OF NORMAL
BIOLOGICAL PROCESSES, PATHOGENIC PROCESSES, OR PHARMACOLOGIC

– 2 –
END OF PAGE 2

START OF PAGE 3
WES MOORE, Governor Ch. 323

RESPONSES TO A SPECIFIC THERAPEUTIC INTERVENTION, INCLUDING KNOWN
GENE–DRUG INTERACTIONS FOR MEDICATIONS BEING CONSIDERED FOR USE OR
ALREADY BEING ADMINISTERED.

(II) “BIOMARKER” INCLUDES GENE MUTATIONS,
CHARACTERISTICS OF GENES, OR PROTEIN EXPRESSION.

(3) (I) “BIOMARKER TESTING” IS THE ANALYSIS OF A PATIENT’S
TISSUE, BLOOD, OR OTHER BIOSPECIMEN FOR THE PRESENCE OF A BIOMARKER,
THE RESULTS OF WHICH:

1. PROVIDE INFORMATION THAT MAY BE USED IN THE
FORMULATION OF A TREATMENT OR MONITORING STRATEGY THAT INFORMS A
PATIENT’S OUTCOME AND IMPACTS THE CLINICAL DECISION; AND

2. INCLUDE BOTH INFORMATION THAT IS ACTIONABLE
AND SOME INFORMATION THAT CANNOT BE IMMEDIATELY USED IN THE
FORMULATION OF A CLINICAL DECISION.

(II) “BIOMARKER TESTING” INCLUDES SINGLE–ANALYTE
TESTS, MULTI–PLEX PANEL TESTS, PROTEIN EXPRESSION, AND WHOLE EXOME,
WHOLE GENOME, AND WHOLE TRANSCRIPTOME SEQUENCING.

(B) THIS SECTION APPLIES TO:

(1) INSURERS AND NONPROFIT HEALTH SERVICE PLANS THAT
PROVIDE HOSPITAL, MEDICAL, OR SURGICAL BENEFITS TO INDIVIDUALS OR GROUPS
ON AN EXPENSE–INCURRED BASIS UNDER HEALTH INSURANCE POLICIES OR
CONTRACTS THAT ARE ISSUED OR DELIVERED IN THE STATE; AND

(2) HEALTH MAINTENANCE ORGANIZATIONS THAT PROVIDE
HOSPITAL, MEDICAL, OR SURGICAL BENEFITS TO INDIVIDUALS OR GROUPS UNDER
CONTRACTS THAT ARE ISSUED OR DELIVERED IN THE STATE.

(C) AN ENTITY SUBJECT TO THIS SECTION SHALL PROVIDE COVERAGE FOR
BIOMARKER TESTING FOR THE PURPOSE OF DIAGNOSIS, TREATMENT, APPROPRIATE
MANAGEMENT, OR ONGOING MONITORING OF A DISEASE OR CONDITION THAT IS
SUPPORTED BY MEDICAL AND SCIENTIFIC EVIDENCE, INCLUDING TESTING:

(1) CLEARED OR APPROVED BY THE U.S. FOOD AND DRUG
ADMINISTRATION;

– 3 –
END OF PAGE 3

START OF PAGE 4
Ch. 323 2023 LAWS OF MARYLAND

(2) REQUIRED OR RECOMMENDED FOR A DRUG APPROVED BY THE
U.S. FOOD AND DRUG ADMINISTRATION TO ENSURE AN INSURED OR ENROLLEE IS
A GOOD CANDIDATE FOR THE DRUG TREATMENT;

(3) REQUIRED OR RECOMMENDED THROUGH A WARNING OR
PRECAUTION FOR A DRUG APPROVED BY THE U.S. FOOD AND DRUG
ADMINISTRATION TO IDENTIFY WHETHER AN INSURED OR ENROLLEE WILL HAVE AN
ADVERSE REACTION TO THE DRUG TREATMENT OR DOSAGE;

(4) COVERED UNDER A CENTERS FOR MEDICARE AND MEDICAID
SERVICES NATIONAL COVERAGE DETERMINATION OR MEDICARE
ADMINISTRATIVE CONTRACTOR LOCAL COVERAGE DETERMINATION; OR

(5) SUPPORTED BY NATIONALLY RECOGNIZED CLINICAL PRACTICE
GUIDELINES THAT ARE:

(I) DEVELOPED BY INDEPENDENT ORGANIZATIONS OR
MEDICAL PROFESSIONAL SOCIETIES USING A TRANSPARENT METHODOLOGY AND
REPORTING STRUCTURE AND THAT HAVE A CONFLICT OF INTEREST POLICY; AND

(II) ESTABLISHED STANDARDS OF CARE INFORMED BY A
SYSTEMATIC REVIEW OF EVIDENCE AND AN ASSESSMENT OF THE BENEFITS AND
RISKS OF ALTERNATIVE CARE OPTIONS AND INCLUDE RECOMMENDATIONS
INTENDED TO OPTIMIZE PATIENT CARE; OR

(6) SUPPORTED BY CONSENSUS STATEMENTS THAT ARE:

(I) DEVELOPED BY AN INDEPENDENT, MULTIDISCIPLINARY
~~PANEL~~ ~~OF~~ ~~EXPERTS~~ ~~USING~~ ~~A~~ ~~TRANSPARENT~~ ~~METHODOLOGY~~ ~~AND~~ ~~REPORTING~~
STRUCTURE AND THAT HAVE A CONFLICT OF INTEREST POLICY; AND

(II) AIMED AT SPECIFIC CLINICAL CIRCUMSTANCES AND BASE
~~THE~~ ~~STATEMENTS~~ ~~ON~~ ~~THE~~ ~~BEST~~ ~~AVAILABLE~~ ~~EVIDENCE~~ ~~FOR~~ ~~THE~~ ~~PURPOSE~~ ~~OF~~
OPTIMIZING THE OUTCOMES OF CLINICAL CARE.

(D) AN ENTITY SUBJECT TO THIS SECTION SHALL ENSURE THAT THE
COVERAGE REQUIRED UNDER SUBSECTION (C) OF THIS SECTION IS PROVIDED IN A
MANNER THAT LIMITS DISRUPTIONS IN CARE INCLUDING THE NEED FOR MULTIPLE
BIOPSIES OR BIOSPECIMEN SAMPLES.

(E) (1) SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION, THE
COVERAGE REQUIRED UNDER THIS SECTION MAY BE SUBJECT TO THE ANNUAL
DEDUCTIBLES, COPAYMENTS, OR COINSURANCE REQUIREMENTS IMPOSED BY AN

– 4 –
END OF PAGE 4

START OF PAGE 5
WES MOORE, Governor Ch. 323

ENTITY SUBJECT TO THIS SECTION FOR SIMILAR COVERAGES UNDER THE SAME
HEALTH INSURANCE POLICY OR CONTRACT.

(2) THE ANNUAL DEDUCTIBLES, COPAYMENTS, OR COINSURANCE
REQUIREMENTS IMPOSED UNDER PARAGRAPH (1) OF THIS SUBSECTION FOR THE
COVERAGE REQUIRED UNDER THIS SECTION MAY NOT BE GREATER THAN THE
ANNUAL DEDUCTIBLES, COPAYMENTS, OR COINSURANCE REQUIREMENTS IMPOSED
BY THE ENTITY FOR SIMILAR COVERAGES.

(F) (1) AN ENTITY SUBJECT TO THIS SECTION THAT REQUIRES PRIOR
~~AUTHORIZATION~~ ~~OR~~ ~~A~~ ~~SIMILAR~~ ~~UTILIZATION~~ ~~REVIEW~~ ~~PROCEDURE~~ ~~FOR~~ ~~THE~~
COVERAGE REQUIRED UNDER SUBSECTION (C) OF THIS SECTION SHALL MAKE A
~~DETERMINATION~~ ~~REGARDING~~ ~~A~~ ~~REQUEST~~ ~~FOR~~ ~~APPROVAL~~ ~~WHEN~~ ~~SUBMITTED~~
~~ELECTRONICALLY:~~

(I) IN REAL TIME IF THE BIOMARKER TESTING IS TO GUIDE THE
~~PROVISION~~ ~~OF~~ ~~PHARMACEUTICAL~~ ~~SERVICES~~ ~~THAT~~ ~~ARE~~ ~~URGENT~~ ~~AND~~ ~~NO~~
ADDITIONAL INFORMATION IS NEEDED TO PROCESS THE REQUEST; AND

(II) FOR OTHER REQUESTS, IN ACCORDANCE WITH §
19–108.2 OF THE HEALTH – GENERAL ARTICLE.

(2) IF A RESPONSE TO A PRIOR AUTHORIZATION OR SIMILAR
~~UTILIZATION~~ ~~REVIEW~~ ~~REQUEST~~ ~~FOR~~ ~~APPROVAL~~ ~~IS~~ ~~NOT~~ ~~RECEIVED~~ ~~IN~~ ~~THE~~ ~~TIME~~
FRAMES REQUIRED UNDER THIS SUBSECTION, THE REQUEST SHALL BE
CONSIDERED APPROVED.

SECTION 2. AND BE IT FURTHER ENACTED, That on or before December 1,
2024, the Maryland Department of Health shall report to the Governor and, in accordance
with § 2–1257 of the State Government Article, the General Assembly on the following:

(1) the fiscal impact of the ~~biomarkers~~ biomarker testing coverage required
under Section 1 of this Act on the Maryland Medical Assistance Program’s policy on
~~biomarkers~~ biomarker testing coverage for specific cancers during fiscal year 2024;

(2) any available data on use of ~~biomarkers~~ biomarker testing by race and
ethnicity in the Program;

(3) the anticipated fiscal and access impacts of expanding the coverage
required under Section 1 of this Act to the Maryland Medical Assistance Program in fiscal
year 2026; ~~and~~

(4) whether to establish a cap on the amount of reimbursement for
biomarker testing coverage and, if recommended:

– 5 –
END OF PAGE 5

START OF PAGE 6
Ch. 323 2023 LAWS OF MARYLAND

(i) the recommended cap amount; and

(ii) the anticipated fiscal and access impacts of establishing the cap;
and

~~(4)~~ (5) recommendations on any legislative changes to the requirements
established under Section 1 of this Act relating to the Maryland Medical Assistance
Program, including managed care organizations.

SECTION 3. AND BE IT FURTHER ENACTED, That on or before December 1,
2025, the Maryland Health Care Commission shall report to the Senate Finance Committee
and the House Health and Government Operations Committee, in accordance with §
2–1257 of the State Government Article, on the impact of providing biomarker testing
coverage required under Section 1 of this Act, including an analysis of the impact of
providing access to biomarker testing to individuals based on race, gender, age, and public
or private insurance.

SECTION ~~2.~~ 4. AND BE IT FURTHER ENACTED, That Section 1 of this Act shall
apply to all policies, contracts, and health benefit plans issued, delivered, or renewed in the
State on or after January 1, 2024.

SECTION ~~3.~~ 5. AND BE IT FURTHER ENACTED, That this Act shall take effect
January 1, 2024.

Approved by the Governor, May 3, 2023.

– 6 –
END OF PAGE 6